mrna-vaccine

Documents about mrna-vaccine

• A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)#829909ClinicalTrials.gov
• Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine#154737ClinicalTrials.gov
• New Generation mRNA Booster Vaccine Against Emerging VOCs#848019ClinicalTrials.gov
• Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine#261344ClinicalTrials.gov
• Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial#205423Europe PMC
• From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine#202203Europe PMC
• Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors#982271ClinicalTrials.gov
• NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants#253545Europe PMC
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations#903646ClinicalTrials.gov
• mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults#238192ClinicalTrials.gov
• Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults#825540ClinicalTrials.gov
• Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine#969158ClinicalTrials.gov
• Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly#979351ClinicalTrials.gov
• Clinical Trial of SARS-CoV-2 mRNA Vaccine in China#253061ClinicalTrials.gov
• A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19#838001ClinicalTrials.gov
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients#874707ClinicalTrials.gov
• Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination#905641ClinicalTrials.gov
• Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People#238172ClinicalTrials.gov
• Points-to-consider: the mRNA vaccine reflection paper#70160J-STAGE (Japan)
• A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine#839686ClinicalTrials.gov
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults#838330ClinicalTrials.gov
• Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants#968841ClinicalTrials.gov
• Raw data of Multiepitope mRNA vaccine against Fasciola hepatica confers T-cell-mediated protection in mice [Dataset]#339934Gestión del Repositorio Documental de la Universidad de Salamanca
• A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine#876651ClinicalTrials.gov
• Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine#467623ClinicalTrials.gov
• COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities#831341ClinicalTrials.gov
• Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors#414364ClinicalTrials.gov
• Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.#1010099ClinicalTrials.gov
• PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.#234508ClinicalTrials.gov
• MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer#481793ClinicalTrials.gov
• Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults#847716ClinicalTrials.gov
• Study of Ameliorating Effect of COVID-19 mRNA Vaccine in Individuals Immunized With Inactivated Vaccine#136409ClinicalTrials.gov
• Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos#890084ClinicalTrials.gov
• Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE#840130ClinicalTrials.gov
• A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants#856924ClinicalTrials.gov
• VaxLab: integrated platform for rapid multistrategy mRNA vaccine design.#159776NCBI PubMed Central
• Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma#226256ClinicalTrials.gov
• Antigen anisotropy: The overlooked geometric determinant of vaccine immunogenicity and fidelity#4585Europe PMC
• Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong#838720ClinicalTrials.gov
• Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma#850681ClinicalTrials.gov
• Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies#224209Europe PMC
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age#992948ClinicalTrials.gov
• Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs#143653ClinicalTrials.gov
• Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform.#297244NCBI PubMed Central
• Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy#344567HAL (France)
• Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates#467627ClinicalTrials.gov
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above#1008766ClinicalTrials.gov
• A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)#343699ClinicalTrials.gov
• Sustained antigen-specific CD8+ T cell immunity post–mRNA booster requires notch pathway activation#280344HAL (France)
• A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age#969196ClinicalTrials.gov